Evaluates KRAS G12D inhibitor efficacy in pancreatic cancer, suggesting obesity alters treatment response.
Previous studies indicate that Diet-induced-obesity (DIO) promotes pancreatic tumor progression, immunosuppression, and resistance to chemotherapy. Here, we evaluated the impact of DIO on efficacy of KRAS
No takes yet. Share an insight, caveat, or question.
Sarvesh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: